A Deliberate Pause: Active Surveillance as a Shared Private-Care Decision

A private consultant has reviewed the scans and blood tests and recommends monitoring rather than immediate treatment. For many patients and families, the phrase watch and wait can sound like a pause in care, or even a polite way of postponing a decision. In contemporary private practice, however, active surveillance is usually something more structured: a planned series of tests, review appointments and pre-agreed points at which the plan will be reconsidered.

The distinction matters. Active surveillance is not the absence of a plan. It is a plan with a purpose, agreed between clinician and patient, and reviewed at defined intervals. For UK patients considering private care in 2026, understanding that structure can turn an anxious wait into a manageable, shared decision.

What active surveillance actually means

Active surveillance is the close monitoring of a condition that is not currently causing harm and does not need immediate treatment. The aim is to avoid unnecessary intervention while remaining ready to act if the condition changes. It is most often discussed in low-risk prostate cancer, where regular PSA testing, MRI scanning and, in some cases, repeat biopsy are used to track the disease.

The same principle can apply to other conditions. Examples include small renal masses that appear low risk, some thyroid nodules, certain blood abnormalities and selected cases of Barrett's oesophagus. In each case, the consultant is balancing the benefit of treatment against the burden of treatment: side effects, recovery time, anxiety and cost.

Active surveillance should also be distinguished from watchful waiting. Watchful waiting is generally a less intensive approach, often used when treatment would be unlikely to change overall wellbeing, for example in some older or frail patients. Active surveillance is more proactive, with a defined schedule of investigations and a clear intention to offer curative treatment if agreed triggers are met.

Why a consultant may recommend monitoring

For low-risk prostate cancer, the case for active surveillance is well established. Many such cancers grow slowly and may never cause symptoms. Surgery and radiotherapy carry real risks, including urinary, bowel and sexual side effects. Monitoring can allow a patient to live well without those risks while keeping treatment available if needed.

That does not mean surveillance is always comfortable. Some patients find the uncertainty harder than the tests. A good private service acknowledges this openly. The question is not simply whether monitoring is clinically appropriate, but whether it is appropriate for this patient, with this level of anxiety, at this stage of life. A shared decision may reasonably include a preference for treatment even when monitoring is an option, and that choice deserves respect.

The programme in practice: scans, tests and reviews

In private care, active surveillance is usually led by a consultant with a special interest in the condition. For prostate cancer, a typical programme might include PSA testing every three to six months in the first year, periodic MRI scans, and repeat biopsy depending on the initial risk and subsequent results. Review appointments may be face to face or remote, but the results should always be discussed by a clinician who knows the case.

Patients should ask for the monitoring schedule in writing. A useful schedule states which test is due, when it is due, who will review the result and how the patient will be contacted. It should also say what happens if a result is borderline or if an appointment is missed. Private providers can often arrange tests quickly, but they are not emergency services. Patients should retain a route back to their NHS GP and ensure that relevant private results are shared, with consent, so that records remain joined up.

Continuity is important. Where possible, the same consultant and the same imaging centre should review the series of scans, because subtle changes are easier to interpret over time. Patients should keep their own folder of results and clinic letters, and should not assume that one provider will automatically obtain records from another.

What monitoring typically costs in 2026

Private active surveillance is usually charged fee for fee rather than as a single package. Costs vary by provider, region and clinical complexity, so any figures are illustrative rather than fixed. In 2026, an initial private consultant appointment commonly falls in the region of £150 to £300, with follow-up appointments often between £100 and £200. A PSA test may cost around £50 to £100. A private MRI scan might be £400 to £900, while a prostate biopsy, including pathology, could be £1,000 to £2,000 or more.

Across a year, monitoring for low-risk prostate cancer might therefore cost several hundred to well over £1,000 depending on the tests required. Patients should request a written estimate before the programme begins, listing what is included and what would trigger additional fees. Those using private medical insurance should check whether active surveillance is covered, whether each test needs separate pre-authorisation, and whether annual limits apply. A monitoring plan that is affordable in year one may need review if the schedule intensifies.

Agreeing triggers for changing course

The most important conversation in active surveillance is often the one about triggers. Before monitoring begins, patients should ask what specific changes would prompt a recommendation for treatment. For prostate cancer, this may include a sustained rise in PSA, a change on MRI, or evidence of higher-grade disease on repeat biopsy. For other conditions, it may be growth in the size of a nodule, new symptoms or a change in blood markers.

Triggers should be as concrete as the clinical picture allows. Patients should also ask how quickly a change would be acted upon, what treatment options would then be available, and whether they can request an earlier review if anxiety becomes difficult. A good plan includes a safety net: clear symptoms to report promptly, and a named contact for questions between appointments.

Making monitoring manageable

Active surveillance works best when it is treated as a partnership. Keep a simple calendar of tests and reviews. Ask for copies of results and clinic letters. Bring a companion to key appointments if that helps recall and confidence. Write questions down beforehand, and ask for plain-English explanations of what each result means.

It is also reasonable to discuss the emotional side. Some patients benefit from speaking to a clinical nurse specialist, a GP or a counsellor. Private providers may offer such support directly or through referral. Monitoring should not feel like being left alone with a diary of dates.

Questions to ask before agreeing

Before starting active surveillance, patients may wish to ask: What is the evidence that monitoring is safe for my condition? What is the exact schedule of tests? Who will review each result? What would count as a trigger for treatment? How often will the plan be reviewed? What are the costs, including likely extras? What should I do if I develop new symptoms? And who do I contact if I am worried between appointments?

A calm conclusion

Active surveillance is better understood as active stewardship of a diagnosis. It avoids treatment that may not be needed while preserving the option of timely intervention. In private care, its value depends on a clear schedule, transparent costs and agreed triggers. With those in place, watch and wait becomes something more reassuring: a deliberate, shared decision made with expert care, close to home.